GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioCryst Pharmaceuticals Inc (MEX:BCRX) » Definitions » E10

BioCryst Pharmaceuticals (MEX:BCRX) E10 : MXN-22.26 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is BioCryst Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

BioCryst Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was MXN-2.711. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is MXN-22.26 for the trailing ten years ended in Dec. 2024.

During the past 3 years, the average E10 Growth Rate was -5.10% per year. During the past 5 years, the average E10 Growth Rate was -4.90% per year. During the past 10 years, the average E10 Growth Rate was -2.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of BioCryst Pharmaceuticals was 7.00% per year. The lowest was -6.50% per year. And the median was -3.20% per year.

As of today (2025-04-05), BioCryst Pharmaceuticals's current stock price is MXN155.00. BioCryst Pharmaceuticals's E10 for the quarter that ended in Dec. 2024 was MXN-22.26. BioCryst Pharmaceuticals's Shiller PE Ratio of today is .


BioCryst Pharmaceuticals E10 Historical Data

The historical data trend for BioCryst Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals E10 Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.08 -17.12 -19.10 -20.92 -22.26

BioCryst Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.92 -21.60 -17.44 -24.38 -22.26

Competitive Comparison of BioCryst Pharmaceuticals's E10

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Shiller PE Ratio falls into.


;
;

BioCryst Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioCryst Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-2.711/133.1571*133.1571
=-2.711

Current CPI (Dec. 2024) = 133.1571.

BioCryst Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201503 -3.201 99.621 -4.279
201506 0.941 100.684 1.244
201509 -3.380 100.392 -4.483
201512 -4.299 99.792 -5.736
201603 -5.336 100.470 -7.072
201606 -4.069 101.688 -5.328
201609 -3.094 101.861 -4.045
201612 -1.237 101.863 -1.617
201703 -3.578 102.862 -4.632
201706 -3.796 103.349 -4.891
201709 -3.267 104.136 -4.177
201712 -3.928 104.011 -5.029
201803 -4.724 105.290 -5.974
201806 -3.733 106.317 -4.675
201809 -5.237 106.507 -6.547
201812 -4.909 105.998 -6.167
201903 -5.431 107.251 -6.743
201906 -6.531 108.070 -8.047
201909 -6.712 108.329 -8.250
201912 -0.377 108.420 -0.463
202003 -5.628 108.902 -6.882
202006 -5.540 108.767 -6.782
202009 -5.744 109.815 -6.965
202012 -6.763 109.897 -8.194
202103 -7.359 111.754 -8.768
202106 -4.777 114.631 -5.549
202109 -6.785 115.734 -7.806
202112 -2.051 117.630 -2.322
202203 -7.964 121.301 -8.742
202206 -6.438 125.017 -6.857
202209 -4.626 125.227 -4.919
202212 -7.408 125.222 -7.877
202303 -5.047 127.348 -5.277
202306 -6.858 128.729 -7.094
202309 -3.310 129.860 -3.394
202312 -5.262 129.419 -5.414
202403 -2.821 131.776 -2.851
202406 -1.099 132.554 -1.104
202409 -1.378 133.029 -1.379
202412 -2.711 133.157 -2.711

Add all the adjusted EPS together and divide 10 will get our e10.


BioCryst Pharmaceuticals  (MEX:BCRX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


BioCryst Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCryst Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.